Stentplasty offers a controlled rescue strategy in refractory intracranial atherosclerotic disease
Endovascular treatment of intracranial atherosclerotic disease has long been constrained by a narrow therapeutic margin. Aggressive medical therapy remains the benchmark because prior intervention studies have exposed the hazards of manipulating tight intracranial stenoses, where perforator injury, distal embolization, and abrupt vessel closure can turn an attempted rescue into a new ischemic event. In this two-center experience, investigators used expandable and retrievable devices for a strategy described as stentplasty, aiming to dilate the artery in a controlled way while avoiding the full vessel injury that can accompany conventional balloon angioplasty.
Eighteen patients underwent treatment after failing maximal medical therapy. Sixteen arrived with acute ischemic stroke and two with transient ischemic attacks, and the median admission NIHSS was 9, with an interquartile range of 6 to 21. These were not mild, incidental lesions discovered on screening angiography; they were symptomatic, high-grade stenoses in patients already past the point where medication alone had prevented further neurologic decline. Median stenosis measured 95% before intervention, a degree of narrowing that leaves very little physiologic reserve for antegrade flow or plaque stability.
Device-assisted dilation reduced stenosis without routine permanent implant use
The procedural concept was simple but clinically meaningful. Expandable retrievable devices were used to achieve submaximal vessel enlargement, with the goal of restoring flow without immediate permanent scaffolding unless the vessel remained too compromised to maintain patency. In 11 patients, stentplasty alone achieved successful reperfusion, defined as modified Thrombolysis in Cerebral Infarction scores of 2b to 3. Seven patients required rescue therapy with permanent stenting, reflecting a subgroup in which temporary dilation was not enough to secure an acceptable luminal result.
A single sentence captures the core procedural tradeoff: one-size-fits-all angioplasty was not the answer.
Median stenosis fell from 95% before treatment to 50% after stentplasty. Among those who went on to receive a permanent stent, stenosis decreased further to 10%. The numbers matter because they show a stepwise pathway rather than an all-or-none maneuver: first, the artery is opened enough to improve flow and assess the response; then, if recoil or residual narrowing remains unacceptable, permanent stenting supplies the final structural correction. In a disease driven by plaque burden and luminal compromise, controlled expansion may be safer than forcing an aggressive single-step dilation across a rigid intracranial segment.
Safety signals were limited, but embolization remained a real procedural hazard
One periprocedural complication occurred, distal embolization in 6% of the cohort. No series of this size can define the full risk profile of the technique, yet the presence of even one embolic event is clinically important because it reflects the vulnerability of atherosclerotic plaque during any mechanical intervention. Distal embolization is exactly the complication interventionalists work to avoid when navigating intracranial arteries, where the downstream territory may be unforgiving and collateral support variable.
The experience did not reveal recurrent ischemic strokes or reocclusions during follow-up. That is a relevant observation in a setting where the main fear after a technically successful procedure is later failure from thrombosis, recoil, or progression of the same atherosclerotic lesion. Follow-up ranged from 30 to 180 days, and all patients reached a modified Rankin Scale score of 0 to 2 at 90 days. Functional recovery after severe symptomatic stenosis depends on more than vessel caliber alone, but the combination of acute reperfusion, low recurrence, and favorable disability scores suggests that flow restoration translated into bedside benefit for this small cohort.
Why a retrievable approach may fit intracranial plaque biology
Intracranial atherosclerotic lesions are not simply narrow tubes to be forced open. Their biology includes plaque rigidity, endothelial injury, local thrombogenicity, and a risk of perforator compromise when the vessel wall is overexpanded. A retrievable device can offer a middle path between medical therapy alone and a permanently deployed stent from the start. By allowing controlled dilation without flow arrest, the approach may preserve perfusion during the maneuver while limiting the vessel trauma that can accompany balloon inflation in a highly constrained intracranial segment.
The practical appeal lies in adaptability. Some lesions respond to temporary enlargement and remain adequately open. Others recoil or remain critically narrowed and need a permanent implant to achieve durable recanalization. The two-center experience captured both patterns, which makes the strategy clinically more flexible than a fixed procedural algorithm. It also explains why the investigators framed stentplasty as a rescue option for patients already refractory to maximal medical therapy rather than as a replacement for first-line management.
What the cohort can and cannot support
This was a small observational series, and the sample size limits any strong claim about comparative efficacy. There was no randomized control group, so the results cannot establish superiority over balloon angioplasty, permanent stenting, or continued medical management. The follow-up window was also variable, extending from one month to six months, which leaves long-term durability uncertain for a disease known to recur over time. Even so, the absence of recurrent ischemic strokes or reocclusions during follow-up is encouraging in a cohort that had already failed medication and presented with severe neurologic events.
The population was also highly selected. Only patients with symptomatic high-grade stenosis between 70% and 99% who failed medical therapy were included, which means these findings apply to a narrow, high-risk subset rather than the broader ICAD population. In everyday practice, that distinction matters because most patients with intracranial stenosis will still be managed medically unless they develop recurrent symptoms despite optimized therapy. For those who do fail, however, the study provides a concrete procedural option with measurable luminal gain and a limited observed complication burden.
A final point deserves emphasis. The treatment goal was not complete normalization of the vessel at all costs, but rather the smallest effective intervention that restored flow and stabilized the artery. In symptomatic intracranial atherosclerosis, that restraint may be the difference between useful recanalization and a catastrophic procedural complication.